.jetcityimage/iStock Editorial via Getty Images Morgan Stanley has opted for Eli Lilly (NYSE: LLY) as its own best biopharma selection for 2025 and measured yet another nine labels in the area as overweight. The expenditure financial institution mentioned in a details that it continues to feel “diabesity is set to become.